Skip to main content
Premium Trial:

Request an Annual Quote

Stephan Herrera, Nassim Usman

Premium
Nektar Therapeutics, which is developing drugs based on proprietary pulmonary and pegylation technology platforms, this week appointed Stephan Herrera as its senior director of investor relations and corporate affairs.
 
Previously, Herrera held a similar role at Sirna Therapeutics, which was acquired by Merck earlier this year (see RNAi News, 1/4/2007). At Nektar, Herrera will work under President and CEO Howard Robin, who was formerly president and CEO of Sirna.
 

 
 
RXi Pharmaceuticals, the RNAi drugs spin out of CytRx, said this week that it has appointed Catalyst Biosciences CEO Nassim Usman to its scientific advisory board.
 
Prior to joining Catalyst, Usman held several positions at Sirna Therapeutics, including vice president of research and development, CSO, and COO. Usman left Sirna in 2005 (see RNAi News, 4/8/2005).

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.